73 related articles for article (PubMed ID: 1953797)
1. Characteristics of various synthetic peptide calpain inhibitors and their application for the analysis of platelet reaction.
Ariyoshi H; Shiba E; Kambayashi J; Sakon M; Tsujinaka T; Uemura Y; Mori T
Biochem Int; 1991 Apr; 23(6):1019-33. PubMed ID: 1953797
[TBL] [Abstract][Full Text] [Related]
2. Potential participation of calpain in platelet activation studied by use of a cell penetrating calpain inhibitor (calpeptin).
Tsujinaka T; Ariyoshi H; Uemura Y; Sakon M; Kambayashi J; Mori T
Life Sci; 1990; 46(15):1059-66. PubMed ID: 2110278
[TBL] [Abstract][Full Text] [Related]
3. The effects of calpeptin (a calpain specific inhibitor) on agonist induced microparticle formation from the platelet plasma membrane.
Yano Y; Shiba E; Kambayashi J; Sakon M; Kawasaki T; Fujitani K; Kang J; Mori T
Thromb Res; 1993 Sep; 71(5):385-96. PubMed ID: 8236165
[TBL] [Abstract][Full Text] [Related]
4. Regulation of plasma membrane Ca2+-ATPase in human platelets by calpain.
Brown CS; Dean WL
Platelets; 2007 May; 18(3):207-11. PubMed ID: 17497432
[TBL] [Abstract][Full Text] [Related]
5. Stimulation of human platelet Ca(2+)-ATPase and Ca2+ restoration by calpain.
Ariyoshi H; Shiba E; Kambayashi J; Sakon M; Kawasaki T; Yoshida K; Mori T
Cell Calcium; 1993 Jun; 14(6):455-63. PubMed ID: 8395339
[TBL] [Abstract][Full Text] [Related]
6. Calpain inhibition by calpeptin does not prevent APLT activity reduction in PS-exposing platelets, but calpeptin has independent pro-apoptotic effects.
Gwozdz AM; Leung R; Wang H; Bang KW; Packham MA; Freedman J; Rand ML
Thromb Haemost; 2010 Jun; 103(6):1218-27. PubMed ID: 20352156
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effect of GBH on platelet aggregation through inhibition of intracellular Ca2+ mobilization in activated human platelets.
Park WH; Kim HK; Nam KS; Shon YH; Jeon BH; Moon SK; Kim MG; Kim CH
Life Sci; 2004 Nov; 75(25):3063-76. PubMed ID: 15474558
[TBL] [Abstract][Full Text] [Related]
8. SNARE protein degradation upon platelet activation: calpain cleaves SNAP-23.
Lai KC; Flaumenhaft R
J Cell Physiol; 2003 Feb; 194(2):206-14. PubMed ID: 12494459
[TBL] [Abstract][Full Text] [Related]
9. Differential regulation of platelet aggregation and aminophospholipid exposure by calpain.
Bachelot-Loza C; Badol P; Brohard-Bohn B; Fraiz N; Cano E; Rendu F
Br J Haematol; 2006 May; 133(4):419-26. PubMed ID: 16643450
[TBL] [Abstract][Full Text] [Related]
10. 2-(2-Br-phenyl)-8-methoxy-benzoxazinone (HPW-RX2), a direct thrombin inhibitor with a suppressive effect on thromboxane formation in platelets.
Wu CC; Wang TW; Wang WY; Hsieh PW; Wu YC
Eur J Pharmacol; 2005 Dec; 527(1-3):37-43. PubMed ID: 16313903
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of a new cell penetrating calpain inhibitor (calpeptin).
Tsujinaka T; Kajiwara Y; Kambayashi J; Sakon M; Higuchi N; Tanaka T; Mori T
Biochem Biophys Res Commun; 1988 Jun; 153(3):1201-8. PubMed ID: 2839170
[TBL] [Abstract][Full Text] [Related]
12. Inositol polyphosphate 4-phosphatase is inactivated by calpain-mediated proteolysis in stimulated human platelets.
Norris FA; Atkins RC; Majerus PW
J Biol Chem; 1997 Apr; 272(17):10987-9. PubMed ID: 9110986
[TBL] [Abstract][Full Text] [Related]
13. Anti-platelet activity of KR-32560, a novel sodium/hydrogen exchanger-1 inhibitor.
Lee KS; Jin YR; Lee JJ; Lim Y; Son DJ; Lee CK; Yi KY; Yoo SE; Shin HS; Yun YP
Pharmacol Res; 2006 Mar; 53(3):265-70. PubMed ID: 16420980
[TBL] [Abstract][Full Text] [Related]
14. An antithrombotic agent, NQ301, inhibits thromboxane A2 receptor and synthase activity in rabbit platelets.
Jin YR; Cho MR; Lee KS; Lee JJ; Lim Y; Han XH; Oh KW; Hong JT; Yoo HS; Yun YP
Basic Clin Pharmacol Toxicol; 2005 Sep; 97(3):162-7. PubMed ID: 16128910
[TBL] [Abstract][Full Text] [Related]
15. Mepacrine blockade of arachidonate-induced washed platelet aggregation: relationship to mepacrine inhibition of platelet cyclooxygenase.
Raz A
Thromb Haemost; 1983 Dec; 50(4):784-6. PubMed ID: 6420923
[TBL] [Abstract][Full Text] [Related]
16. Licofelone, an inhibitor of cyclooxygenase and 5-lipoxygenase, specifically inhibits cyclooxygenase-1-dependent platelet activation.
Rotondo S; Krauze-Brzósko K; Manarini S; Evangelista V; Cerletti C
Eur J Pharmacol; 2004 Mar; 488(1-3):79-83. PubMed ID: 15044038
[TBL] [Abstract][Full Text] [Related]
17. The anti-aggregation effects of ondansetron on platelets involve IP3 signaling and MAP kinase pathway, but not 5-HT3-dependent pathway.
Liu FC; Liou JT; Liao HR; Mao CC; Yang P; Day YJ
Thromb Res; 2012 Sep; 130(3):e84-94. PubMed ID: 22818390
[TBL] [Abstract][Full Text] [Related]
18. Antiplatelet effect of sanguinarine is correlated to calcium mobilization, thromboxane and cAMP production.
Jeng JH; Wu HL; Lin BR; Lan WH; Chang HH; Ho YS; Lee PH; Wang YJ; Wang JS; Chen YJ; Chang MC
Atherosclerosis; 2007 Apr; 191(2):250-8. PubMed ID: 16797553
[TBL] [Abstract][Full Text] [Related]
19. In vitro antiplatelet profiles of the new thromboxane synthetase inhibitor sodium 2-(1-imidazolylmethyl)-4,5-dihydrobenzo[b]thiophene-6-carboxylate.
Asai F; Ito T; Ushiyama S; Matsuda K; Oshima T
Arzneimittelforschung; 1991 May; 41(5):506-10. PubMed ID: 1898421
[TBL] [Abstract][Full Text] [Related]
20. A role for the intracellular protease calpain in the activation of store-operated calcium entry in human platelets.
Harper AG; Sage SO
Cell Calcium; 2007 Feb; 41(2):169-78. PubMed ID: 16884770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
